Australia Hemostatic Instruments Market Size, Share, Growth and Forecast, 2025-2035

Surgery and endoscopy growth widen bleeding control use

The Australia hemostatic instruments market was valued at USD 60.5 million in 2025 and is projected to increase from USD 71.0 million in 2026 to USD 128.6 million by 2035, registering a CAGR of 6.82% during 2026–2035. Demand comes from public and private hospitals that control bleeding during cardiac, orthopedic, abdominal and general surgery, and from endoscopy units that treat gastrointestinal bleeds with clips, powders and thermal tools. New South Wales and Australian Capital Territory held the largest regional share, 33.7% in 2025, because the zone has the most hospitals and surgeons. Queensland and Northern Territory is the fastest-growing region at 7.23% a year, as population growth adds procedures. In turn, the federal government confirmed in May 2024 that general use items would stay funded on the national device list, which kept private reimbursement in place for many surgical consumables.

Which bleeding control products does the estimate cover?

The estimate measures the value of passive topical hemostats such as gelatin, collagen, cellulose and starch products, active hemostats and fibrin sealants, endoscopic clips, powders and thermal devices, and mechanical clamps, clips and compression instruments used to stop bleeding. It counts purchases by public hospital networks, private hospital groups and independent day and endoscopy providers.

The estimate excludes blood products given by transfusion, systemic drugs that change clotting, and general energy platforms sold mainly for cutting. The value chain runs from global manufacturers through Australian subsidiaries, specialist distributors and wholesalers to hospital theaters and endoscopy suites.

Topical agents lead while endoscopic devices grow fastest

Why do passive topical hemostats lead value?

Based on product type, the market is categorized into passive topical hemostats, active hemostats and fibrin sealants, endoscopic hemostasis devices and mechanical hemostatic instruments. Passive Topical Hemostats led with a 34.0% share of 2025 value, because gelatin, collagen and plant-based products are used in most operating theaters. Endoscopic Hemostasis Devices grow fastest at 7.94% a year, as endoscopists treat more bleeds with clips and powders.

How do cardiac and gastrointestinal cases split use?

Based on disease area, the market is categorized into gastrointestinal bleeding, cardiovascular conditions, musculoskeletal conditions and abdominal and soft-tissue conditions. Cardiovascular Conditions led with a 30.0% share of 2025 value, because cardiac and vascular surgery uses sealants and patches on large suture lines. Gastrointestinal Bleeding grows fastest at 7.77% a year, as screening programs send more patients for colonoscopy.

Why do public hospital networks buy the most?

Based on end user, the market is categorized into public hospital networks, private hospital groups and independent procedural providers. Public Hospital Networks led with a 48.0% share of 2025 value, because they treat most emergency, trauma and complex cases. Independent Procedural Providers grow fastest at 7.80% a year, as doctor-owned day surgeries and endoscopy centers open across the major cities.

How do manufacturers and distributors reach hospitals?

Based on sales channel, the market is categorized into manufacturer direct sales, specialist distributor sales and medical wholesaler sales. Manufacturer Direct Sales led with 55.0% of 2025 value, because large device makers hold hospital contracts and train surgeons in theater. Specialist Distributor Sales grow fastest at 7.25% a year, as smaller brands and new agents reach private and day hospitals through focused local partners.

Funded surgery, endoscopy tools and new agents lift demand

How does funded procedural throughput lift product use?

Funded procedural throughput lifts product use, because nearly every operation needs some form of bleeding control. Public hospitals recorded 791,000 elective surgery admissions in 2024–25, with a median wait of 45 days, according to national data reported by Scimex. Private hospitals performed 1,827,599 surgeries in 2023-24 and carry about 70% of all planned surgery in Australia. Insured hospital episodes also reached 1,306,750 in the June 2025 quarter, up 2.2% over 12 months. Emergency departments also handled 9.1 million presentations in 2024–25, which adds trauma and acute bleeding cases. As a result, public hospital networks hold 48.0% of 2025 value, while private groups add steady volume through insured elective cases.

Why does therapeutic endoscopy product breadth widen demand?

Therapeutic endoscopy product breadth widens demand, because clips, powders and thermal tools let endoscopists stop bleeds without surgery. Australians undergo about 1 million colonoscopies each year, according to the Australian Commission on Safety and Quality in Health Care. The national bowel screening program screened about 2.6 million people, and 86,089 participants in 2023 needed further assessment after a positive result. Olympus Australia sponsors a short-term gastrointestinal endoscopic clip on the national register, while Cook Medical markets Hemospray powder for nonvariceal bleeds. In turn, endoscopic hemostasis devices grow at 7.94% a year, the fastest product rate, as hospitals add endoscopy devices and accessories.

Download Free Sample

How does advanced agent portfolio development change buying?

Advanced agent portfolio development changes buying, because manufacturers now offer patches, powders and sealants that work faster and store more easily. Baxter launched a room-temperature version of Hemopatch across Australia and New Zealand in the 2025-26 summer, with a shelf life of up to 36 months, according to a Jan. 21, 2026, release. The national register lists Hemopatch as a collagen agent sponsored by Baxter Healthcare. BD markets Arista AH plant-based powder in Australia with a five-year shelf life, citing a randomized trial of 288 patients. As a result, active products and fibrin sealants gain ground in cardiac, liver and urological surgery.

Why do insurance coverage and an aging population support use?

Insurance coverage and an aging population support use, because older patients need more cardiac, joint and abdominal operations. People aged 65 and over made up 18.1% of the Australian population in 2025, according to the World Bank. Some 12,531,009 people, or 45.4% of the population, held private hospital cover at June 30, 2025, according to the Australian Prudential Regulation Authority. Insurer benefits for medical devices reached AUD 622.08 million in that quarter, up 12.4%, with cardiac devices the largest group at 17.8%. In turn, cardiovascular conditions hold 30.0% of 2025 value, because cardiac and vascular operations use the most sealants and patches per case.

Day surgery, ready-to-use formats and access gaps shape use

How is the shift to day surgery changing purchases?

The shift to day surgery is changing purchases, because more short procedures now take place outside large hospitals. Australia had 637 private hospitals including day surgeries in July 2025, and doctor-owned day surgeries have been the main type of new opening since 2020, according to the private hospitals association. Same-day cases made up 74.1% of private hospital admissions in 2023-24, or 3,812,478 admissions. About 80 private hospitals have also closed since 2020, which moves cases toward the remaining sites and newer day centers. As a result, independent procedural providers grow at 7.80% a year, the fastest end-user rate, and favor compact, ready-to-use products that need little storage space.

Why is the rise of ready-to-use formats notable?

The rise of ready-to-use formats is notable, because theater teams want products that need no mixing, thawing or refrigeration. Baxter removed the need for cold storage with its room-temperature Hemopatch, which it launched in New Zealand in September 2025 before the wider regional rollout. BD sells Arista AH in 1 g, 3 g and 5 g powder sizes with long applicators for laparoscopic use. Cook Medical states that Hemospray contains no human or animal proteins and sprays from a carbon dioxide cartridge. In turn, flowable hemostats and dry powders gain use in minimally invasive procedures, where surgeons must reach bleeding sites through small ports and need products that are ready the moment they are opened.

Download Free Sample

Can closing colonoscopy access gaps open new demand?

Closing colonoscopy access gaps can open new demand, because many regional and lower-income Australians receive fewer procedures than city residents. Colonoscopy rates were about four times higher in major cities, at 2,550 per 100,000 people, than in remote areas, at 633, in 2023-24. Rates in the most affluent areas were also nearly double those in the most disadvantaged areas, at 3,067 against 1,675 per 100,000. Bowel screening participation reached only 41.7% for invitations issued in 2022 and 2023. Australians undergo about 1 million colonoscopies a year, so even small gains in regional access add many procedures. As a result, gastrointestinal bleeding grows fastest at 7.77% a year as access widens.

Is there room to grow as device funding rules settle?

Suppliers have room to grow as device funding rules settle, because private hospitals and insurers now know how surgical consumables will be paid. The federal government announced on May 1, 2024, that 475 general use items, including surgical glues, would stay on the national device list, according to the Department of Health. It then consulted on general use item growth from Aug. 9 to Sept. 20, 2024. Sponsors could apply to list new items with a listed comparator from the November 2024 list. In turn, makers of patches, sealants and electrosurgical devices can plan launches with more certainty, because private hospitals know which items insurers will fund.

Benefit cuts, closures and evidence demands test suppliers

How do benefit cuts pressure product prices?

Benefit cuts pressure product prices, because the federal government cut general use item benefits by 60% of the gap to public prices on July 1, 2022, and by a further 40% on March 1, 2023. As a result, private hospitals now negotiate harder on consumable prices. Suppliers respond with value bundles, clinical training and evidence on time saved in theater, which helps them defend premium products in tenders and keep their place on hospital formularies.

Why do private hospital closures shift buying patterns?

Private hospital closures shift buying patterns, because about 80 private hospitals have closed since 2020 while new openings are mostly small day surgeries. In turn, suppliers lose some large overnight accounts and must serve many smaller sites with different product needs. Companies respond with smaller pack sizes, distributor partners and remote ordering, which keeps service costs under control across scattered customers. Day surgeries also tend to stock fewer brands, which raises the stakes of every tender.

How do evidence demands slow new product uptake?

Evidence demands slow new product uptake, because hospital product committees ask for clinical data and cost comparisons before adding a new agent to theater stock. As a result, newer powders and patches can take months to win formulary approval. Suppliers respond with local surgeon trials, published outcome data and training sessions, which help clinicians compare products on time to bleeding control and cost per case. This evidence work adds real cost for smaller suppliers and new brands.

Why do long waits and staffing limits cap volumes?

Long waits and staffing limits cap volumes, because public hospitals can only run as many theater and endoscopy lists as their staff allow. Some 6.0% of public elective surgery patients waited more than a year in 2024–25. In turn, product use grows more slowly than clinical need. States respond with surgery blitzes and outsourcing to private hospitals, which moves some volume to private and day surgery sites and spreads product demand.

New South Wales leads as Queensland grows fastest

Why do new South Wales and the ACT hold the top share?

New South Wales and Australian Capital Territory held a 33.7% share of 2025 value and grow at 6.63% a year, because the zone has the largest population and the most surgical hospitals. Its population grew by about 103,000 people in the year to March 2026. Sydney also hosts major cardiac, transplant and trauma centers that use sealants and patches heavily. As a result, the zone leads both theater and endoscopy demand.

How do Victoria and Tasmania support demand?

Victoria and Tasmania held a 24.6% share of 2025 value and grow at 6.83% a year, because Melbourne has a dense network of public and private hospitals. The zone added about 113,000 people in the year to March 2026, the largest increase of any zone. In turn, private hospitals in Victoria handled 36% of state admissions in 2023-24, which keeps insured surgery volumes high.

Download Free Sample

Why are Queensland and the Northern Territory growing fastest?

Queensland and Northern Territory held a 20.2% share of 2025 value and grow fastest at 7.23% a year, because Queensland gains residents through both interstate and overseas migration. The zone added about 94,000 people in the year to March 2026. Private hospitals also handled 42% of Queensland admissions in 2023-24. As a result, new day surgeries and endoscopy centers in south-east Queensland lift demand.

What shapes demand in Western Australia and South Australia?

Western Australia and South Australia held a 21.5% share of 2025 value and grow at 6.73% a year, because Perth and Adelaide hold most of the zone's surgical capacity. Western Australia had the fastest population growth rate of any state in the year to March 2026. Private hospitals handled 44.2% of Western Australian admissions in 2023-24.

Download Free Sample

Funding, screening data and launches, 2024–2026

Powders, patches and endoscopic clips change care

• Plant-based and collagen agents absorb blood and form a matrix at the bleeding site, which suits oozing from wide surfaces in open and laparoscopic surgery. Room-temperature patches and powders with long shelf lives also simplify theater stock.
• Endoscopic clips and powders close or cover bleeding vessels in the gut during colonoscopy or gastroscopy, which helps patients avoid surgery. Mineral powders can treat larger bleeding areas that clips cannot reach easily.
• Mechanical and thermal instruments clamp, compress or seal vessels directly, which gives surgeons control over larger bleeds during cardiac, vascular and abdominal operations.

Global device makers compete through direct hospital sales

Competition is led by global device makers that sell directly to hospitals through Australian subsidiaries. Baxter launched a room-temperature version of Hemopatch across Australia and New Zealand and lists the product on the national register. BD markets Arista AH plant-based powder to Australian and New Zealand surgeons, while Johnson & Johnson MedTech offers its oxidized regenerated cellulose Surgicel Powder to Australian clinicians. Olympus Australia sponsors a gastrointestinal endoscopic clip, while Cook Medical, which has its Australian headquarters in Brisbane, markets Hemospray powder for gut bleeds. Rivals compete on speed to bleeding control, ease of use, shelf life, clinical evidence and price. Because hospital committees decide which agents stay in theater stock, suppliers with strong clinical training teams win more contracts. Specialist distributors and wholesalers also help smaller brands reach day surgeries and regional hospitals that large sales teams visit less often.

Which companies supply Australian hospitals?

Credence Research view on surgical bleeding control demand

Credence Research's view is that Australian demand for bleeding control products will grow steadily because surgery and endoscopy volumes keep rising with an older population. Passive topical agents remain the largest value pool, while endoscopic devices add the fastest growth as screening and therapeutic colonoscopy expand. Settled funding rules for surgical consumables should support new launches in private hospitals. Suppliers that combine strong clinical evidence, easy storage and training should gain share fastest, while benefit cuts will keep prices under pressure.

How the national bleeding control estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines hospital activity statistics, private health insurance data, population statistics, national device funding publications, screening program reports and company product announcements. Segment splits and zone growth rates are Credence Research estimates, while zone shares follow the client-defined split. Sources used are official statistics, government releases, industry association data and company releases, and no interviews or surveys were used.

Endoscopy and day surgery carry growth to 2035

Product value is expected to reach USD 128.6 million by 2035, a 6.82% CAGR during 2026–2035, as hospitals perform more surgery and endoscopy for an older population. Growth should be strongest through 2030 while day surgeries and endoscopy centers open. After that, replacement of older agents with faster patches and powders will carry more value. Stronger public surgery funding would lift volumes, while deeper benefit cuts would slow price growth. Suppliers with strong evidence and training are expected to gain the most.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.